June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Two years outcomes in eyes receiving aflibercept according to fixed 2 month interval for neovascular age-related macular degeneration: observational study dataTwo years outcomes in eyes receiving aflibercept according to fixed 2 month interval for neovascular age-related macular degeneration: observational study data
Author Affiliations & Notes
  • Koji Kanda
    National Defense Medical Collage, Tokorozawa-shi, Saitama, Japan
  • Tomohito Sato
    National Defense Medical Collage, Tokorozawa-shi, Saitama, Japan
  • Manzo Taguchi
    National Defense Medical Collage, Tokorozawa-shi, Saitama, Japan
  • Hideaki Someya
    National Defense Medical Collage, Tokorozawa-shi, Saitama, Japan
  • Toshihiko Murata
    National Defense Medical Collage, Tokorozawa-shi, Saitama, Japan
  • Masaru Takeuchi
    National Defense Medical Collage, Tokorozawa-shi, Saitama, Japan
  • Footnotes
    Commercial Relationships   Koji Kanda, None; Tomohito Sato, None; Manzo Taguchi, None; Hideaki Someya, None; Toshihiko Murata, None; Masaru Takeuchi, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2164. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Koji Kanda, Tomohito Sato, Manzo Taguchi, Hideaki Someya, Toshihiko Murata, Masaru Takeuchi; Two years outcomes in eyes receiving aflibercept according to fixed 2 month interval for neovascular age-related macular degeneration: observational study dataTwo years outcomes in eyes receiving aflibercept according to fixed 2 month interval for neovascular age-related macular degeneration: observational study data. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2164.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Purpose: To investigate 2-year visual and anatomic outcomes of eyes with intravitreal aflibercept injection according to fixed 2 month interval for neovascular age-related macular degeneration (nAMD).

Methods : Methods: Retrospective, single-practice data analysis from a medical record system. A total of 12 eyes (12 patients) with treatment-naive nAMD receiving aflibercept every-2-months for 2 years were reviewed. The primary study outcome was VA in decimal notation converted to minimal angle of resolution scores, and the secondary outcomes were optical coherence tomography (OCT) findings including: central retinal thickness (CRT) and subretinal/intraretinal fluid (SRF/IRF)

Results : Results: Mean age of patients was 71.2 years (median: 71.5, min: 55, max 86) at baseline. Occult with no classic CNV was 3 eyes (25%), predominantly classic lesions was 5 eyes (42%), and indocyanine-green angiography revealed polypoidal choroidal vasculopathy was 4 eyes (33%). Mean VA was 0.73 at baseline, 0.58 at 3 months, 0.58 at 6 months, 0.55 at 1 year, and 0.40 at 2 years (P < .05). CRT decreased from 322.3 μm at baseline to 282.8 μm at 3 months, 298.9 μm at 6 months, 248.3 μm at 1 year, and 261.8 μm at 2 years (P < .01). At 2 years, 7 eyes (58%) were considered as inactive by absence of intraretinal or subretinal fluid on OCT, however 5 eyes (42%) remained active with the presence of SRF, IRF, intraretinal cysts, or macular haemorrhage. Mean VA at 2 years in the active and inactive groups were 0.52 and 0.31, respectively (P = .59). Mean CRT at 2 years in the active and inactive groups were 321.8 μm and 290.0 μm (P = .14).

Conclusions : Conclusions: Intravitreal aflibercept administration with fixed 2 month interval for 2 years improved both visual acuity and macular morphology, although number of eyes with nAMD investigated in the present study was small. In addition, eyes with active lesions at 2 years do not have worse visual acuity compared with those with inactive lesions.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×